Insulet Corp. logo
PODDInsulet Corp.

Current vs Average Return on Invested Capital (ROIC)

Return on Invested Capital (ROIC)

How the latest reported return on invested capital (roic) of 13.62% compares to its TTM/3Y/5Y/10Y/15Y/20Y averages as of Wednesday, December 31, 2025.

PODD Return on Invested Capital (ROIC)

PODD Current vs Average Return on Invested Capital (ROIC)

PODD Return on Invested Capital (ROIC) vs Average

CURRENT VS TTM AVG

+7.67%

CURRENT VS 3Y AVG

+51.84%

CURRENT VS 5Y AVG

+87.43%

CURRENT VS 10Y AVG

+537.80%

CURRENT VS 15Y AVG

+460.26%

CURRENT VS 20Y AVG

+550.32%

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy